Xeris Biopharma Holdings (XERS) Stock Overview
A commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 3/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
XERS Community Fair Values
Create NarrativeSee what 17 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Xeris Biopharma Holdings, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$6.18 |
| 52 Week High | US$10.08 |
| 52 Week Low | US$4.30 |
| Beta | 0.90 |
| 1 Month Change | -5.36% |
| 3 Month Change | 6.19% |
| 1 Year Change | 37.95% |
| 3 Year Change | 120.32% |
| 5 Year Change | n/a |
| Change since IPO | 161.86% |
Recent News & Updates
Narrative Update • Jun 03
XERS: Higher 2026 Revenue Guidance Will Support Stronger Medium Term Cash Expectations
Analysts have adjusted their price target on Xeris Biopharma Holdings to $8.00, citing updated assumptions for revenue growth, profit margins, and future P/E that slightly refine rather than change their existing valuation view. What's in the News Xeris Biopharma Holdings raised its full year 2026 revenue guidance to a range of US$380 million to US$390 million.Seeking Alpha • May 31
Xeris Looks Ridiculously Cheap If Growth Forecasts Are Even Halfway Right
Summary Xeris Biopharma has delivered another year of significant revenue growth, signaling a pivotal moment in its trajectory. XERS has reached an inflection point, indicating a shift in its business momentum and future prospects. The article highlights the company's expanding injectable medication portfolio as a driver for recent and anticipated growth. Strong recent performance and portfolio execution underpin confidence in XERS's forward-looking investment thesis. Read the full article on Seeking AlphaAnalysis Article • May 15
Shareholders Will Be Pleased With The Quality of Xeris Biopharma Holdings' (NASDAQ:XERS) Earnings
The subdued stock price reaction suggests that Xeris Biopharma Holdings, Inc.'s ( NASDAQ:XERS ) strong earnings didn't...Narrative Update • May 14
XERS: Raised 2026 Revenue Guidance Will Support Stronger Medium Term Cash Expectations
Analysts have maintained their price target for Xeris Biopharma Holdings at $8.00, citing updated assumptions that reflect slightly higher discount rates, more moderate revenue growth expectations of 20.31%, a profit margin of 13.67%, and a future P/E of 27.67x. What's in the News Xeris Biopharma raised its full year 2026 total revenue guidance to a range of $380m to $390m, with management indicating confidence in meeting full year financial targets (Corporate Guidance, Raised).Recent updates
Narrative Update • Jun 03
XERS: Higher 2026 Revenue Guidance Will Support Stronger Medium Term Cash Expectations
Analysts have adjusted their price target on Xeris Biopharma Holdings to $8.00, citing updated assumptions for revenue growth, profit margins, and future P/E that slightly refine rather than change their existing valuation view. What's in the News Xeris Biopharma Holdings raised its full year 2026 revenue guidance to a range of US$380 million to US$390 million.Seeking Alpha • May 31
Xeris Looks Ridiculously Cheap If Growth Forecasts Are Even Halfway Right
Summary Xeris Biopharma has delivered another year of significant revenue growth, signaling a pivotal moment in its trajectory. XERS has reached an inflection point, indicating a shift in its business momentum and future prospects. The article highlights the company's expanding injectable medication portfolio as a driver for recent and anticipated growth. Strong recent performance and portfolio execution underpin confidence in XERS's forward-looking investment thesis. Read the full article on Seeking AlphaAnalysis Article • May 15
Shareholders Will Be Pleased With The Quality of Xeris Biopharma Holdings' (NASDAQ:XERS) Earnings
The subdued stock price reaction suggests that Xeris Biopharma Holdings, Inc.'s ( NASDAQ:XERS ) strong earnings didn't...Narrative Update • May 14
XERS: Raised 2026 Revenue Guidance Will Support Stronger Medium Term Cash Expectations
Analysts have maintained their price target for Xeris Biopharma Holdings at $8.00, citing updated assumptions that reflect slightly higher discount rates, more moderate revenue growth expectations of 20.31%, a profit margin of 13.67%, and a future P/E of 27.67x. What's in the News Xeris Biopharma raised its full year 2026 total revenue guidance to a range of $380m to $390m, with management indicating confidence in meeting full year financial targets (Corporate Guidance, Raised).Analysis Article • May 09
Results: Xeris Biopharma Holdings, Inc. Confounded Analyst Expectations With A Surprise Profit
It's been a good week for Xeris Biopharma Holdings, Inc. ( NASDAQ:XERS ) shareholders, because the company has just...Narrative Update • Apr 30
XERS: 2026 Revenue Guidance Will Support Bullish Medium Term Cash Expectations
Analysts have kept their price target on Xeris Biopharma Holdings steady at $8.00, citing updated assumptions for slightly higher revenue growth, a modestly lower profit margin, and a largely unchanged forward P/E outlook. What's in the News Xeris Biopharma issued earnings guidance for the full year 2026, giving investors a concrete reference point for medium term expectations (Key Developments).
Narrative Update • Apr 15
XERS: 2026 Revenue Outlook Will Support Stronger Future Cash Generation
Analysts have adjusted their price target on Xeris Biopharma Holdings to $17.23, reflecting updated views on revenue growth, profit margin expectations, and future P/E assumptions, while maintaining their overall fair value estimate at the same $17.23 level. What's in the News Xeris Biopharma issued earnings guidance for the full year 2026, giving investors a clearer view of expected financial results.Narrative Update • Apr 01
XERS: Rising Long Term Revenue Outlook Will Support Bullish Cash Expectations
Analysts have revised their price target on Xeris Biopharma Holdings to $8.00, unchanged from the prior $8.00. This reflects updated views on revenue growth assumptions, profit margins, and future P/E expectations, while leaving their fair value estimate steady.
Narrative Update • Mar 18
XERS: Higher 2025–2026 Revenue Guidance Will Support Future Cash Generation
Analysts have adjusted their price target on Xeris Biopharma Holdings to $11.14, with the change mainly tied to updated assumptions for revenue growth, profit margins, and a higher future P/E multiple. What's in the News Xeris Biopharma issued new full year 2026 guidance, targeting total revenue in a range of US$375 million to US$390 million (Corporate guidance).Narrative Update • Mar 03
XERS: Higher 2025–2026 Revenue Guidance Will Support Future Cash Generation
Analysts have reduced their price target on Xeris Biopharma Holdings to $21.03 from $25.82, reflecting a lower assumed future P/E multiple while now modeling slightly higher revenue growth and profit margins. What's in the News Xeris Biopharma issued new earnings guidance for full year 2026, projecting total revenue in a range of $375 million to $390 million.Narrative Update • Feb 17
XERS: Once-Weekly Levothyroxine Platform Will Drive Future Cash Generation
Analysts have slightly lowered their price outlook for Xeris Biopharma Holdings, trimming their fair value estimate from about $11.50 to roughly $11.14 as they recalibrate assumptions around the discount rate, long-term profit margin, and future P/E expectations. What's in the News Xeris Biopharma Holdings updated its full-year 2025 earnings guidance, now expecting total revenue of approximately US$292 million.Narrative Update • Feb 03
XERS: Expanding Hypercortisolism Market Will Support Stronger Future Cash Generation
Analysts have lifted their price target on Xeris Biopharma Holdings to US$8 from US$6, pointing to recent quarterly results and expectations that Recorlev's role in an expanding hypercortisolism space could support more durable cash generation. Analyst Commentary Bullish analysts are framing the higher US$8 price target as a reflection of what they see as solid execution on both the income statement and the product portfolio, rather than a single quarter story.Narrative Update • Jan 20
XERS: Expanding Hypercortisolism Market And Q3 Delivery Support Measured Cash Outlook
Analysts have raised their price target on Xeris Biopharma Holdings to $8 from $6, citing recent Q3 results that were closely in line with Street expectations, as well as continued support from Recorlev in an expanding hypercortisolism market, as drivers of their updated view. Analyst Commentary Analysts highlighting the new US$8 price target are framing it as a reset based on currently reported numbers rather than a call on aggressive upside.Narrative Update • Jan 06
XERS: Expanding Hypercortisolism Opportunity Will Support Future Cash Generation Potential
Analysts have lifted their price target on Xeris Biopharma to $8 from $6, citing recent Street research that points to steady revenue performance, Q3 earnings in line with expectations, and an outlook for sustainable cash generation supported by Recorlev in the expanding hypercortisolism treatment space. Analyst Commentary The latest Street research frames Xeris Biopharma as a company with a clearer path to cash generation, but also one where execution and growth pacing still matter a lot for valuation.Narrative Update • Dec 15
XERS: Expanding Hypercortisolism Market Will Drive Stronger Long Term Cash Generation
Analysts have raised their price target for Xeris Biopharma to $8.00 from $6.00, reflecting increased confidence in the company’s accelerating revenue growth, expanding margins, and the sustainable cash generation potential of Recorlev in the growing hypercortisolism market. Analyst Commentary Bullish analysts highlight that the higher price target reflects growing confidence in Xeris Biopharma’s execution against revenue expectations and its ability to sustain momentum in core franchises.Analysis Article • Dec 03
Risks Still Elevated At These Prices As Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Shares Dive 35%
Xeris Biopharma Holdings, Inc. ( NASDAQ:XERS ) shares have had a horrible month, losing 35% after a relatively good...Narrative Update • Dec 01
XERS: Expanding Hypercortisolism Market Presence Will Drive Future Cash Generation
Analysts raised their price target for Xeris Biopharma Holdings from $6 to $8, citing steady revenue growth and expectations for sustained cash generation as a result of the company’s expanding presence in the hypercortisolism market. Analyst Commentary Following recent quarterly results and the upward revision of the price target, analysts provided detailed insights regarding the valuation and execution outlook for Xeris Biopharma Holdings.Narrative Update • Nov 17
XERS: Revenue Momentum and Margin Expansion Will Drive Further Share Appreciation
Analysts have increased their price target for Xeris Biopharma Holdings from $10.67 to $11.50, citing improved revenue growth, stronger profit margins, and ongoing strength in key product segments. Analyst Commentary Recent street research has provided insight into both the opportunities and challenges facing Xeris Biopharma Holdings following its latest earnings announcement and price target adjustments.Narrative Update • Nov 02
XERS: Higher 2025 Revenue Guidance Will Drive Measured Financial Outlook
Analysts have raised their price target for Xeris Biopharma Holdings from $9.00 to $10.67, citing updated fair value assessments and recalibrated forecasts for the company’s financial outlook. What's in the News Xeris Biopharma Holdings raised its full-year 2025 total revenue guidance to $280 to $290 million, up from the prior range of $260 to $275 million (Key Developments).Analysis Article • Oct 16
There's Reason For Concern Over Xeris Biopharma Holdings, Inc.'s (NASDAQ:XERS) Massive 26% Price Jump
Xeris Biopharma Holdings, Inc. ( NASDAQ:XERS ) shares have continued their recent momentum with a 26% gain in the last...Narrative Update • Aug 23
Expanding Patient Demand And Pipeline Launches Will Reshape Healthcare Markets
Driven by improvements in net profit margin and revenue growth forecasts, analysts have raised their fair value estimate for Xeris Biopharma Holdings from $8.17 to $9.00. What's in the News Xeris Biopharma Holdings raised full-year 2025 revenue guidance to $280–$290 million, up from the prior range of $260–$275 million.Analysis Article • Aug 10
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Analysts Are Pretty Bullish On The Stock After Recent Results
NasdaqGS:XERS 1 Year Share Price vs Fair Value Explore Xeris Biopharma Holdings's Fair Values from the Community and...Narrative Update • Aug 08
Expanding Patient Demand And Pipeline Launches Will Reshape Healthcare Markets
The significant upward revision in Xeris Biopharma Holdings’ price target reflects rising future P/E expectations despite a decline in net profit margin, resulting in a fair value increase from $6.30 to $7.80. What's in the News Xeris Biopharma Holdings raised full-year 2025 total revenue guidance to $280-$290 million from $260-$275 million.Analysis Article • Jul 15
A Piece Of The Puzzle Missing From Xeris Biopharma Holdings, Inc.'s (NASDAQ:XERS) 25% Share Price Climb
Xeris Biopharma Holdings, Inc. ( NASDAQ:XERS ) shareholders have had their patience rewarded with a 25% share price...New Narrative • May 05
Advancing Recorlev, Gvoke And XP-8121 Will Drive Future Demand
Strategic investments in Recorlev and untapped Gvoke markets may significantly boost long-term revenue, aligning with medical guidelines to meet growing patient demands.Seeking Alpha • Mar 16
Xeris Biopharma: Low Risk, Low Excitement Solid Revenue Generator
Summary Xeris Biopharma has strong revenue growth, with net product revenue reaching $203 million in 2024 and projected to hit $255–275 million in 2025. Key products include Gvoke for severe hypoglycemia, Keveyis for Primary Periodic Paralysis, and Recorlev for Cushing's Syndrome, with Recorlev showing strong growth. The company has a promising pipeline with XP-8121, a once-weekly levothyroxine injection for hypothyroidism, showing positive phase 2 data. Despite a decline in Keveyis revenue, Xeris remains a low-risk, stable company with a positive outlook under new management. Read the full article on Seeking AlphaAnalysis Article • Mar 16
Investors Appear Satisfied With Xeris Biopharma Holdings, Inc.'s (NASDAQ:XERS) Prospects As Shares Rocket 34%
Despite an already strong run, Xeris Biopharma Holdings, Inc. ( NASDAQ:XERS ) shares have been powering on, with a gain...Analysis Article • Mar 07
An Intrinsic Calculation For Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Suggests It's 47% Undervalued
Key Insights Xeris Biopharma Holdings' estimated fair value is US$7.76 based on 2 Stage Free Cash Flow to Equity Xeris...Analysis Article • Jan 30
Some Shareholders Feeling Restless Over Xeris Biopharma Holdings, Inc.'s (NASDAQ:XERS) P/S Ratio
It's not a stretch to say that Xeris Biopharma Holdings, Inc.'s ( NASDAQ:XERS ) price-to-sales (or "P/S") ratio of 2.9x...Seeking Alpha • Oct 25
Xeris Biopharma Holdings: Promising Pipeline And Strategic Partnerships Make It Attractive
Summary Xeris Biopharma Holdings, Inc. is an overlooked specialty pharmaceutical company with three FDA-approved products, utilizing its proprietary XeriSol and XeriJect technologies to develop innovative injectable drug formulations. Gvoke and Recorlev drive Xeris' rapid growth, with Gvoke holding 34% of the retail glucagon market and Recorlev expanding its patient base by 124%. Xeris' strategic partnerships and promising pipeline, particularly XP-8121 for hypothyroidism, offer strong potential for value creation and long-term growth. Xeris is a Strong Buy due to its solid growth, innovative technology platforms, and strategic efforts aimed at driving shareholder value. Read the full article on Seeking AlphaAnalysis Article • Sep 07
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Could Be Riskier Than It Looks
With a price-to-sales (or "P/S") ratio of 2.1x Xeris Biopharma Holdings, Inc. ( NASDAQ:XERS ) may be sending bullish...Analysis Article • Jun 04
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Stock Rockets 30% But Many Are Still Ignoring The Company
Xeris Biopharma Holdings, Inc. ( NASDAQ:XERS ) shareholders are no doubt pleased to see that the share price has...Seeking Alpha • Mar 30
Xeris Biopharma: Checking-In On One Of My 'Top Ideas'
Summary Xeris Biopharma has not yet achieved cash flow breakeven and may no longer be a "Top Idea" in the Compounding Healthcare Investing Group. Xeris has three approved products and a strong pipeline, with potential for market penetration and revenue growth. Risks include competition from larger healthcare companies and the FDA approval of a generic version of one of Xeris' products, Keveyis. Read the full article on Seeking AlphaAnalysis Article • Mar 09
Analysts Are Updating Their Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Estimates After Its Full-Year Results
There's been a major selloff in Xeris Biopharma Holdings, Inc. ( NASDAQ:XERS ) shares in the week since it released its...Shareholder Returns
| XERS | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 1.8% | 3.3% | -2.5% |
| 1Y | 37.9% | 40.0% | 22.7% |
Return vs Industry: XERS underperformed the US Pharmaceuticals industry which returned 40.4% over the past year.
Return vs Market: XERS exceeded the US Market which returned 22.8% over the past year.
Price Volatility
| XERS volatility | |
|---|---|
| XERS Average Weekly Movement | 6.2% |
| Pharmaceuticals Industry Average Movement | 10.1% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: XERS has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: XERS's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 435 | John Shannon | www.xerispharma.com |
Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase 3 clinical trial for the treatment of hypothyroidism.
Xeris Biopharma Holdings, Inc. Fundamentals Summary
| XERS fundamental statistics | |
|---|---|
| Market cap | US$1.07b |
| Earnings (TTM) | US$12.01m |
| Revenue (TTM) | US$314.85m |
88.9x
P/E Ratio3.4x
P/S RatioIs XERS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| XERS income statement (TTM) | |
|---|---|
| Revenue | US$314.85m |
| Cost of Revenue | US$44.42m |
| Gross Profit | US$270.44m |
| Other Expenses | US$258.43m |
| Earnings | US$12.01m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.07 |
| Gross Margin | 85.89% |
| Net Profit Margin | 3.81% |
| Debt/Equity Ratio | 1,700.3% |
How did XERS perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/08 10:23 |
| End of Day Share Price | 2026/06/05 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Xeris Biopharma Holdings, Inc. is covered by 14 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jenna Davidner | Barclays |
| Robin Garner Kalley | Craig-Hallum Capital Group LLC |
| Chase Knickerbocker | Craig-Hallum Capital Group LLC |